1、 Technical and equipment advantages
OEM manufacturers achieve three major technological breakthroughs through specialized equipment:
Cell level wall breaking technology: using an air flow mechanical coupling crushing system, the wall breaking rate of medicinal materials such as Ganoderma spores reaches over 98%, and the effective ingredient dissolution rate is increased by 4 times. Leading enterprises such as Shandong Ruipu Biotechnology are equipped with Swiss Hosokawa classifiers, which can accurately control particle size in the range of 0.1-75 μ m, meeting the new requirements for micron sized powders in the 2025 edition of the Chinese Pharmacopoeia.
Low temperature protection system: liquid nitrogen cryogenic (-50 ℃) combined with water cooling system to prevent thermal sensitive components from denaturing, resulting in a 26% increase in the retention rate of total saponins in Panax notoginseng compared to traditional processes.
Intelligent control capability: The IoT platform monitors real-time parameters such as crushing pressure and temperature, and automatically optimizes processes through AI algorithms to control production capacity fluctuations within 5%.
2、 Cost and compliance advantages
• Conversion of fixed assets investment: enterprises do not need to purchase equipment by themselves (for example, the single CJ series shredder costs 1800000 yuan to 500000 yuan), and can convert fixed costs into pay as you go mode.
Compliance assurance: The OEM provides complete process validation documents, including microbial limit testing (through thermophilic Bacillus subtilis challenge test) and SEM electron microscopy wall breaking rate certification.
• Improved utilization rate of raw materials: Ultra fine grinding increased the extraction rate of active ingredients such as tanshinone IIA by 187%, and reduced the amount of medicinal materials by more than 30%.
3、 Quality and Innovation Advantages
Homogenization treatment: Compound medicinal materials form semi moist particle clusters after cell wall breaking, and the HLB values of each component reach dynamic equilibrium, ensuring uniform release of medicinal effects.
• Formulation innovation support: Powder sizes below 5 μ m can be used for inhalation formulation development.
Microbial control: A closed dust-free system combined with online near-infrared detection ensures that the microbial content of the product is 50% lower than the pharmacopoeia standard limit.